Dr. Boyle’s career spans clinical surgery, vascular research and medical innovation. After starting out his career specializing in cardiothoracic surgery, he now sub specializes entirely in treating patients with vein and vascular disorders. After graduating from the University of Minnesota Medical School, Dr. Boyle completed his surgical training at the University of Washington in Seattle. This included completion of residency training in surgery and sub specialization in cardiovascular and thoracic surgery. During his tenure at the University of Washington, Dr. Boyle also completed a cardiovascular research fellowship where he developed basic science and clinical research programs, primarily focusing on blood vessel disorders at a basic science level.
As a researcher he has published over 80 manuscripts in peer reviewed medical journals and textbooks, mostly on the subject of vascular biology. In addition to obtaining NIH funding, he played the lead role in developing research collaborations with Bayer’s Pharmaceutical Division, Genentech, Zymogenetics/Novo Nordisk, Icos Corporation, US Surgical Corporation (now Covidien) and other privately held biotechnology and device companies. Dr. Boyle’s research has been recognized nationally with awards from the American College of Surgeons, the American Heart Association, The Western Thoracic Surgery Association, the Seattle Surgical Society and others.
In addition to his clinical work, Dr. Boyle is active in surgical innovation. Dr. Boyle was a founder of Elixis, a healthcare information technology company which was acquired by Data Critical Corporation (NASDAQ: DCCA), now a division of General Electric (NYSE: GE). Dr. Boyle is a founder of Clear Catheter Systems, Medical Device Innovations, VenX, and the Device Innovation Group, all early stage medical device companies where he is an inventor on a number of medical devices that relate to minimally invasive surgical techniques or process improvements in healthcare.
He has won innovation awards from the European Association of Cardiothoracic Surgeons, the Medical Design Excellence Award (MDEA) and ID Design. Oregon Business Magazine recently listed him as one of the 50 top business leaders, citing his pioneering work in minimally invasive device innovation. Recently, his work was cited in the R&D 100 list, which salutes the 100 most technologically significant products introduced into the marketplace over the past year. In 2013, his work was awarded the top prize at the Innovations in Cardiovascular Interventions (ICI) conference.